Literature DB >> 2174510

Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes.

R F Bruns1, J H Fergus.   

Abstract

Several 2-amino-3-benzoylthiophenes were found to increase the binding of [3H]N6-cyclohexyladenosine to A1 adenosine receptors in rat brain membranes. Concentration-response curves were bell-shaped, with up to 45% stimulation of binding at 10 microM followed by inhibition at higher concentrations. Because these compounds originated from a series of nonxanthine adenosine antagonists, the inhibition of binding was attributed to the presence of interfering adenosine antagonist activity. The compounds stimulated binding of several A1 agonist ligands but only inhibited binding of the A1 antagonist ligand [3H]8-cyclopentyl-1,3-dipropylxanthine, indicating that enhancement was specific for the agonist conformation of the receptor. The enhancement was also specific for the A1 receptor, because agonist binding to A2 adenosine, M2 muscarinic, alpha 2 adrenergic, and delta opiate receptors showed little or no enhancement. Uncoupling of the A1 receptor from the inhibitory guanine nucleotide-binding protein did not prevent enhancement. The enhancers slowed the dissociation of [3H]N6-cyclohexyladenosine from the A1 receptor, implying an allosteric mechanism of action. The inhibition of forskolin-stimulated cyclic AMP accumulation in FRTL-5 cells was employed as a functional index of A1 receptor activation. The enhancers caused up to 19-fold leftward shifts in the concentration-response curve for N6-cyclopentyladenosine and also caused up to 55% inhibition of cyclic AMP accumulation in the absence of agonist. The binding and functional results are consistent with a model in which the enhancers bind preferentially to the agonist conformation of the A1 receptor, thereby shifting the receptor equilibrium in favor of agonist binding. Adenosine enhancers may be useful for ischemia and other conditions involving local energy deficits. More generally, allosteric enhancers may provide a means for strengthening physiological control circuits in a variety of receptor systems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174510

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  51 in total

1.  Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue.

Authors:  M F Jarvis; C T Wismer; E Schweitzer; H Yu; K J Lynch; E C Burgard; E A Kowaluk
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 2.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

3.  Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives.

Authors:  Z G Gao; J E Van Muijlwijk-Koezen; A Chen; C E Müller; A P Ijzerman; K A Jacobson
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

4.  The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.

Authors:  Samita Bhattacharya; Rebecca L Youkey; Kobina Ghartey; Matthew Leonard; Joel Linden; Amy L Tucker
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

5.  Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.

Authors:  Anikó Göblyös; Zhan-Guo Gao; Johannes Brussee; Roberto Connestari; Sabrina Neves Santiago; Kai Ye; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

6.  Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors.

Authors:  Zhan-Guo Gao; Ariel S Gross; Kenneth A Jacobson
Journal:  Life Sci       Date:  2004-05-07       Impact factor: 5.037

7.  Partial agonism of theophylline-7-riboside on adenosine receptors.

Authors:  A P IJzerman; E M van der Wenden; J K von Frijtag Drabbe Künzel; R A Mathôt; M Danhof; P A Borea; K Varani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

8.  Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions.

Authors:  L T May; S J Briddon; S J Hill
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

Review 9.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

Review 10.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.